^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    4-hydroxytestosterone transdermal (CR 1477)

    i
    Other names: CR-1447, 4-OHT, CR 1477
    Company:
    Curadis
    Drug class:
    Androgen receptor agonist
    8ms
    Final Overall Survival Analysis of the Phase II SAKK 21/12 Trial of Transdermal CR1447 in Patients With Metastatic Breast Cancer. (PubMed, Clin Breast Cancer)
    In this final OS analysis, CR1447 was associated with an OS in line with other ET agents in patients with metastatic ER-positive, HER2-negative breast cancer who had received no more than 1 prior line of ET. Therapy was well tolerated with no treatment-related grade 3 to 5 toxicities.
    P2 data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • AR positive • HER-2 negative + ER positive
    |
    4-hydroxytestosterone transdermal (CR 1477)
    over2years
    Final Overall Survival (OS) analysis of the SAKK 21/12 trial. CR1447 in HR+/HER2- metastatic breast cancer and androgen receptor positive triple negative breast cancer. (SABCS 2023)
    Mutational analysis of AR/ER is ongoing to determine benefit of this treatment in specific subgroups. CR1447 might be a candidate drug to combine with other agents (CDK4/6 inhibitors or other targeted therapies).
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor)
    |
    HER-2 negative • AR positive
    |
    4-hydroxytestosterone transdermal (CR 1477)
    over2years
    SAKK 21/12: CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer (clinicaltrials.gov)
    P2, N=29, Terminated, Swiss Group for Clinical Cancer Research | Trial completion date: Jun 2027 --> Oct 2022 | Active, not recruiting --> Terminated; The SAKK board decided to prematurely end the life-long follow-up of the trial SAKK 21/12, as 90% of the patients have died.
    Trial completion date • Trial termination • Metastases
    |
    4-hydroxytestosterone transdermal (CR 1477)